These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 22432104)

  • 1. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
    Fonseca VA; Alvarado-Ruiz R; Raccah D; Boka G; Miossec P; Gerich JE;
    Diabetes Care; 2012 Jun; 35(6):1225-31. PubMed ID: 22432104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
    Seino Y; Min KW; Niemoeller E; Takami A;
    Diabetes Obes Metab; 2012 Oct; 14(10):910-7. PubMed ID: 22564709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.
    Ratner RE; Rosenstock J; Boka G;
    Diabet Med; 2010 Sep; 27(9):1024-32. PubMed ID: 20722676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
    Rosenstock J; Hanefeld M; Shamanna P; Min KW; Boka G; Miossec P; Zhou T; Muehlen-Bartmer I; Ratner RE
    J Diabetes Complications; 2014; 28(3):386-92. PubMed ID: 24650952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
    Seino Y; Yabe D; Takami A; Niemoeller E; Takagi H
    J Diabetes Complications; 2015; 29(8):1304-9. PubMed ID: 26342556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
    Dailey GE; Dex TA; Roberts M; Liu M; Meneilly GS
    J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).
    Bolli GB; Munteanu M; Dotsenko S; Niemoeller E; Boka G; Wu Y; Hanefeld M
    Diabet Med; 2014 Feb; 31(2):176-84. PubMed ID: 24117597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
    Meneilly GS; Roy-Duval C; Alawi H; Dailey G; Bellido D; Trescoli C; Manrique Hurtado H; Guo H; Pilorget V; Perfetti R; Simpson H;
    Diabetes Care; 2017 Apr; 40(4):485-493. PubMed ID: 28188240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
    Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
    Ahrén B; Leguizamo Dimas A; Miossec P; Saubadu S; Aronson R
    Diabetes Care; 2013 Sep; 36(9):2543-50. PubMed ID: 23536584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
    Seino Y; Ikeda Y; Niemoeller E; Watanabe D; Takagi H; Yabe D; Inagaki N
    Horm Metab Res; 2015 Nov; 47(12):895-900. PubMed ID: 26039935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
    Riddle MC; Aronson R; Home P; Marre M; Niemoeller E; Miossec P; Ping L; Ye J; Rosenstock J
    Diabetes Care; 2013 Sep; 36(9):2489-96. PubMed ID: 23628617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
    Seino Y; Takami A; Boka G; Niemoeller E; Raccah D;
    Diabetes Obes Metab; 2014 Aug; 16(8):739-47. PubMed ID: 24524806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
    Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
    Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.
    Broglio F; Mannucci E; Napoli R; Nicolucci A; Purrello F; Nikonova E; Stager W; Trevisan R
    Diabetes Obes Metab; 2017 Feb; 19(2):248-256. PubMed ID: 27762096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
    Lorenz M; Pfeiffer C; Steinsträsser A; Becker RH; Rütten H; Ruus P; Horowitz M
    Regul Pept; 2013 Aug; 185():1-8. PubMed ID: 23665027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.